SOURCE: Active Biotech

July 16, 2008 02:46 ET

TEVA ENROLLS PATIENTS FOR A SECOND LARGE GLOBAL PHASE III TRIAL OF ORAL LAQUINIMOD

LUND, SWEDEN--(Marketwire - July 16, 2008) - Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. Please visit www.activebiotech.com for more information.

Active Biotech AB
P.O. Box 724
SE-22007 Lund
Tel. +46 46 19 20 00
Fax +46 46 19 20 50







Copyright © Hugin AS 2008. All rights reserved.

Contact Information